Berg—a clinical-stage company that incorporates artificial intelligence (AI) to research various diseases and develop novel treatments for those conditions—is joining forces with pharmaceutical firm Boehringer Ingelheim, using its Interrogative Biology platform. The two firms will work together on research projects centered on better understanding the spectrum of inflammatory diseases, and their associated biological drivers.
According to Berg, the pilot program working with Boehringer Ingelheim is geared toward revealing new insights into the complexities of various inflammatory diseases. The possible outcomes of the research partnership, the participants hope, will lead to an increased understanding of the etiology of potential candidate biomarkers.
Niven Narain (Berg cofounder, president and CEO) said the two companies hope to advance tests and treatments for people diagnosed with such inflammatory diseases.
“We’re excited to partner with Boehringer Ingelheim, which will combine Boehringer Ingelheim’s translational medicine and biomarker expertise with Berg’s next generation AI-driven, patient-biology capability,” he said. “Our intent is for BergInterrogative Biology platform to enable the discovery of biomarkers that will revolutionize how to diagnose and treat patients with inflammatory diseases.
Berg in the past has collaborated with numerous pharmaceutical companies and applied its Interrogative Biology platform to diverse datasets, in order to address major unment clinical needs.
